Monte Rosa Therapeutics (GLUE) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Monte Rosa Therapeutics (NASDAQ: GLUE) is set to announce its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($0.31) per share and revenue of $7.23 million.
• In its last earnings report on May 8th, the company reported earnings of $0.57 per share, exceeding expectations significantly and generating revenue of $84.93 million.
• Monte Rosa Therapeutics has experienced recent changes in institutional investor holdings, with significant purchases, including a 122.7% increase in shares owned by Goldman Sachs Group Inc.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Monte Rosa Therapeutics to post earnings of ($0.31) per share and revenue of $7.23 million for the quarter.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.16. The firm had revenue of $23.19 million for the quarter, compared to the consensus estimate of $7.23 million. Monte Rosa Therapeutics had a net margin of 13.58% and a return on equity of 10.31%. On average, analysts expect Monte Rosa Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Monte Rosa Therapeutics Stock Performance

GLUE traded up $0.15 during mid-day trading on Friday, reaching $4.38. 404,889 shares of the stock were exchanged, compared to its average volume of 449,362. The stock has a market capitalization of $269.41 million, a PE ratio of 12.17 and a beta of 1.42. The company has a 50 day moving average price of $5.00 and a two-hundred day moving average price of $5.16. Monte Rosa Therapeutics has a 1 year low of $3.50 and a 1 year high of $12.40.

Analysts Set New Price Targets

Separately, Wall Street Zen downgraded shares of Monte Rosa Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd.

Institutional Investors Weigh In On Monte Rosa Therapeutics

A number of hedge funds have recently made changes to their positions in GLUE. AQR Capital Management LLC bought a new stake in shares of Monte Rosa Therapeutics during the 1st quarter worth $1,065,000. Goldman Sachs Group Inc. raised its stake in shares of Monte Rosa Therapeutics by 122.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company's stock worth $1,652,000 after purchasing an additional 196,238 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Monte Rosa Therapeutics during the 1st quarter worth $76,000. Finally, Geode Capital Management LLC raised its stake in shares of Monte Rosa Therapeutics by 12.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company's stock worth $5,071,000 after purchasing an additional 120,098 shares during the period. 79.96% of the stock is currently owned by institutional investors.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.